What is Polymyositis?
Polymyositis is a rare idiopathic inflammatory myopathy characterized by symmetric proximal muscle weakness caused by CD8+ cytotoxic T cells invading non-necrotic muscle fibers, distinguished from other inflammatory myopathies by the absence of skin rash and specific histopathological findings. 1
Core Clinical Features
Polymyositis presents with progressive, symmetric proximal muscle weakness developing over weeks to months. Patients experience:
- Difficulty standing from a chair, climbing stairs, or lifting arms overhead 1
- Weakness primarily affecting proximal extremities (shoulders, hips) 2
- Dysphagia and dysphonia when upper esophageal striated muscle is involved 3
- Myalgia in severe cases, though weakness is the predominant symptom 2
Critical distinction: Polymyositis causes true muscle weakness, not just pain. This differentiates it from polymyalgia rheumatica, where patients have pain without actual weakness 2.
Diagnostic Hallmarks
Laboratory Findings
- Creatine kinase (CK) markedly elevated, often 10-50 fold above normal 1, 4
- Elevated inflammatory markers (ESR, CRP) 1
- Myositis-specific autoantibodies typically absent in true polymyositis 5
Histopathology (Gold Standard)
Muscle biopsy is essential and shows: 1, 4
- Endomysial inflammatory infiltrate with CD8+ T cells
- Invasion of non-necrotic muscle fibers expressing MHC-I antigen
- Absence of perimysial pathology (which would suggest dermatomyositis)
- No rimmed vacuoles (which would indicate inclusion body myositis)
Additional Diagnostic Tests
- EMG shows muscle fibrillations indicative of myopathy 2, 6
- MRI demonstrates increased intensity and edema in affected muscles 2, 6
Critical Diagnostic Considerations
Polymyositis is now considered extremely rare because it is a diagnosis of exclusion. 7, 5 Recent evidence shows that only 1.1% of patients initially diagnosed with polymyositis actually meet strict diagnostic criteria after comprehensive re-evaluation 5.
Must Exclude Before Diagnosing Polymyositis:
- Dermatomyositis (look for characteristic rash - heliotrope, Gottron papules)
- Immune-mediated necrotizing myopathy (IMNM) (severe myopathy with minimal inflammation, often statin-associated)
- Antisynthetase syndrome (check for anti-Jo-1 and other synthetase antibodies)
- Inclusion body myositis (asymmetric weakness, rimmed vacuoles on biopsy)
- Muscular dystrophies with inflammation 4
- Toxic myopathies (statins, corticosteroids) 2, 6
- Endocrine and metabolic myopathies 4
Prognosis and Life-Threatening Complications
When polymyositis involves the myocardium or causes fulminant necrotizing course with rhabdomyolysis, it requires urgent treatment to avoid fatal complications. 2, 6 Patients with concomitant myocarditis have an ominous prognosis with high mortality rates 2.
However, strictly defined typical polymyositis has a favorable prognosis when properly diagnosed and treated, with all patients in one study achieving clinical remission at 2-year follow-up 5.
Treatment Approach
High-dose corticosteroids are the cornerstone of initial treatment, administered as bolus in severe cases 6. For refractory or life-threatening cases:
- Plasmapheresis for poor corticosteroid response 6
- Immunosuppressants and IVIG as used for polymyositis/dermatomyositis 6
The 5-year survival rate for treated patients is approximately 95%, though up to one-third may have residual muscle weakness 3.
Key Clinical Pitfall
The major pitfall is overdiagnosis of polymyositis. Many conditions previously labeled as polymyositis are now recognized as distinct entities (antisynthetase syndrome, IMNM, inclusion body myositis misclassified as polymyositis) 7, 5. Always obtain muscle biopsy with immunohistochemistry and comprehensive autoantibody testing before confirming this diagnosis 4, 5.